Form 4: Xeris Biopharma Executive Kenneth Johnson Sells Shares to Cover Tax Obligations

Xeris Biopharma's Senior Vice President, Kenneth Johnson, sold shares to cover tax obligations related to vested restricted stock units.

Summary

• Kenneth Johnson, a Senior Vice President at Xeris Biopharma Holdings, sold a total of 41,318 shares of common stock on January 31, 2025.
• The sales were executed to cover income tax withholding obligations related to the vesting of restricted stock units.
• The shares were sold at a price of $3.56 per share.
• Following these transactions, Mr. Johnson directly owns 320,446 shares of Xeris Biopharma common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment towards the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax liabilities when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales.

Stakeholder Impact

• The stock sales may have a minor impact on the stock price due to the increased supply of shares, but this is likely to be minimal given the relatively small volume of shares sold.

Key Dates

Keywords

Xeris Biopharma, insider trading, stock sale, Form 4, restricted stock units, tax obligations, executive compensation